Navigation Links
Solace Therapeutics, Inc. Announces CE Mark Approval
Date:10/1/2009

FRAMINGHAM, Mass., Oct. 1 /PRNewswire/ -- Solace Therapeutics, Inc., a medical device company focused on the development of non-surgical bladder control therapies announced today that it has received European CE mark approval for the Solace Intravesical System, and ISO 13485:2003 certification for the company's Framingham facility. The company is introducing its first product, an office-based therapy for Female Stress Urinary Incontinence at the International Continence Society Meeting in San Francisco on Friday, October 2, 2009.

"This certification and CE mark approval represent a significant achievement and major milestone for Solace," said Kevin Connors, chief executive officer of Solace Therapeutics. "Successfully completing this process allows us to move forward with the clinical development of the Solace Intravesical System in Europe.

Solace is introducing its first product, a non-surgical therapy for women with Stress Urinary Incontinence, to ICS members at their annual meeting on Friday. "Solace is targeting those patients that are dissatisfied with current therapies and choose to manage their urinary leakage with absorbent pads or diapers," said Connors. "Solace has developed a new option for these patients."

The Solace Balloon is a small lightweight device (about the size of a quarter) that floats within the urinary bladder. It acts as a "shock absorber" to reduce the temporary pressure changes in the bladder that cause urinary leakage. It is placed in the bladder with a soft tube-like catheter and inflated with air. The 5 minute procedure is performed in the physician's office without anesthesia or surgery. No lifestyle change is required after the procedure, and the procedure is reversible at any time.

The Solace Balloon for women with involuntary urine leakage is currently being evaluated in several centers throughout the U.S. in an FDA IDE approved clinical trial. More information about the product is available at www.bladdercomfort.com.

About Solace Therapeutics

Solace Therapeutics is an emerging medical device company focused on the development of non-surgical office based treatments for common bladder disorders, such as stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction and lower urinary tract symptoms (LUTS). Solace is dedicated to improving the patient's quality of life by eliminating side effects typically associated with current drug and surgical therapies. Solace's proprietary technology is designed to offer patients the following benefits:

  • Office-based therapy that does not require anesthesia or surgery
  • No lifestyle change required, before or after treatment
  • Reversible at any time

Solace's patented technology platform is based on the fundamental fluid mechanics principles of reducing rapid pressure changes in fluid with air-based pressure attenuation. Solace is the pioneer of applying these principles to treat bladder dysfunction. More information on Solace contact Kevin Connors at kconnors@solacetx.com or visit www.solacetx.com.

SOURCE Solace Therapeutics, Inc.


'/>"/>
SOURCE Solace Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
8. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
9. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
10. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a ... cells and other difficult to transfect cells, announces its launch of the PluriQ™ ... Gene Editing System is a complete system for culturing and transfecting human ...
Breaking Medicine News(10 mins):